Cancer Management
May 09, 2025
ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions
ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...
Read More...
Nov 09, 2022
Emerging Role of Digital Health in the Field of Oncology
The growth and development in the Digital health technologies, such as mobile health (mHealth) apps, electronic health records (EHRs), electronic medical records (EMRs), wearable devices, telehealth, and telemedicine, as well as personalized medicine, have immensely transformed the healthcare industry and its marke...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
